Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Janux Therapeutics Inc (NQ: JANX )

50.31 +3.81 (+8.19%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics Inc

< Previous 1 2 3 4 5 Next >
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
From Janux Therapeutics
Via Business Wire
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Big Lots, Inc. (NYSE: BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and... 
Via Benzinga
Janux Therapeutics: Q1 Earnings Insights
Via Benzinga
Janux Therapeutics's Return On Capital Employed Overview
Via Benzinga
Why Janux Therapeutics Shares Rose 33.1% This Week
The clinical-stage biotech company just began its first clinical trial. 
Via The Motley Fool
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Beyond Air, Inc. (NASDAQ: XAIR) dipped during Tuesday’s session following weak quarterly results. 
Via Benzinga
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
Exposures US Equities
$27.5M Bet On Block? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. 
Via Benzinga
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Becton, Dickinson and Company, Applied Digital, POSCO And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Janux Therapeutics' Stock Is Currently Undervalued, Analyst Highlights Prostate Cancer Candidate Potential
Janux Therapeutics Inc (NASDAQ: JANX) announced interim Phase 1 clinical data for PSMA-TRACTr JANX007 in adult subjects with metastatic castration- 
Via Benzinga
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
From Janux Therapeutics
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2023
Via Benzinga
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
From Janux Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit... 
Via Benzinga
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
From Janux Therapeutics, Inc.
Via Business Wire
7 Short-Squeeze Stocks for Bold Contrarians to Consider
While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists. 
Via InvestorPlace
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.